Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Takara, Clontech, and Cellartis brands. To keep you up to date with the latest happenings at Takara Bio USA, we have compiled our recent announcements and press releases below.
Advanced Diagnostics Laboratory, LLC granted EUA based on Takara Bio’s high-throughput COVID-19 testing method
Date: August 21, 2020
SmartChip method from Takara Bio USA, Inc. has been approved for use in a COVID-19 diagnostic test through an FDA Emergency Use Authorization awarded to Advanced Diagnostics Laboratory, LLC.
Takara Bio USA, Inc. and bioSyntagma, Inc. develop method for large-scale automated COVID-19 testing
Date: June 8, 2020
Takara Bio USA, Inc. collaborated with bioSyntagma, Inc. and their partners to develop and validate a new high-throughput method for COVID-19 testing, and are seeking an FDA Emergency Use Authorization.
Takara Bio announces completion of a new GMP facility for manufacturing gene and cell therapy products
Date: May 26, 2020
Takara Bio Inc. has completed the construction of a new facility, the Center for Gene and Cell Therapy Processing II (CGCPII) in Shiga, Japan, which has been operational since January 2020.
Namocell, Takara Bio USA and HepaTx collaborate on single cell genomics analysis for cell therapy to treat late-stage liver diseases
Date: February 20, 2020
Namocell Inc., a leading provider of single-cell sorting and dispensing platforms, entered into a collaboration with Takara Bio and HepaTx to use Namocell's Single Cell Dispensers to perform single-cell isolation on HepaTx's unique hepatocyte-like cells (iHeps) and characterize them by single-cell RNA-seq using Takara Bio's SMART-Seq technology.
Takara Bio announces launch of human iPSC-derived intestinal epithelial cells for drug discovery research
Date: November 12, 2019
Takara Bio Inc. has launched the world's first commercially available small intestinal epithelial cells derived from human induced pluripotent stem cells, jointly developed when Takara Bio received a technology transfer from a differentiation induction method to derive these cells from hiPSCs.
Ground-breaking single-cell transcriptomic study using ICELL8 technology reveals homogeneity in mono- and multi-nucleated adult cardiomyocytes
Date: September 9, 2019
Researchers from the Max Planck Institute of Heart and Lung Research are the first to apply single-cell RNA sequencing on intact, adult mouse cardiomyocytes using the ICELL8 Single-Cell System.
Date: May 16, 2019
Researchers at the University of Helsinki, Universidade Católica Portuguesa, CBQF, and Technische Universität Dresden, Institute of Hydrobiology, along with other collaborators have performed the first trans-Europe surveillance study on antibiotic resistance utilizing the SmartChip Real-Time PCR System.
Date: April 11, 2019
Takara Bio USA, Inc. announced today that its parent company, Takara Bio Inc., submitted a Drug Master File to the Food and Drug Administration for the liquid formulation of RetroNectin GMP grade on March 15, 2019.
Date: March 18, 2019
Researchers from Steven Henikoff's laboratory (Fred Hutchinson Cancer Research Center) have developed a novel epigenomic method, CUT&Tag (Cleavage Under Targets and Tagmentation), for high-throughput profiling of chromatin components in single cells on the ICELL8 Single-Cell System.
Date: October 31, 2018
We are pleased and excited to announce that Dr. Christian Hoppmann, Research Scientist at Takara Bio USA, Inc., was awarded an Innovator Award at CPSA USA 2018 following his presentation on Capturem technology.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2020 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.